logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Subarachnoid Hemorrhage

    FiltersReset Filters
    3 results

    • nimodipine

      (Nimodipine)
      BIONPHARMA INC.
      Usage: Nimodipine is indicated to improve neurological outcomes in patients with subarachnoid hemorrhage due to ruptured intracranial berry aneurysms, by reducing the incidence and severity of ischemic deficits, applicable to all post-ictus neurological conditions (Hunt and Hess Grades I-V).

    • nimodipine

      (nimodipine)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Nimodipine is indicated to improve neurological outcomes by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage due to ruptured intracranial berry aneurysms, applicable to all post-ictus neurological conditions (Hunt and Hess Grades I to V).

    • nymalize

      (nimodipine)
      Azurity Pharmaceuticals, Inc.
      Usage: NYMALIZE is indicated for improving neurological outcomes in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, by reducing the incidence and severity of ischemic deficits, irrespective of the patients' neurological condition post-ictus (Hunt and Hess Grades I-V).